<DOC>
	<DOCNO>NCT01309399</DOCNO>
	<brief_summary>Teriparatide potent osteoporosis medication help prevent fracture , however , investigator know little effect hip . The investigator evaluate hip bone sample patient treat teriparatide undergo hip replacement . The information help u understand teriparatide might help reduce hip fracture risk .</brief_summary>
	<brief_title>Early Effects Parathyroid Hormone ( PTH ) Proximal Femur</brief_title>
	<detailed_description>Osteoporosis consequent hip fracture cause substantial disability , morbidity mortality . Teriparatide ( TPTD ) , aminoterminal fragment parathyroid hormone ( PTH ) , increase bone mineral density ( BMD ) bone strength reduce fracture incidence throughout skeleton , data confirm specific efficacy hip fracture never available . Histomorphometric study 18-36 month TPTD treatment show improvements bone volume structure iliac crest . Both biochemical histomorphometric investigation iliac crest early time point ( within 4-6 week administration ) show bone formation dramatically stimulate . Apart beneficial effect TPTD bone density bone strength finite element analysis hip , nothing know mechanism effect TPTD proximal femur . While BMD change small slow hip response TPTD spine , possible stimulation bone formation periosteal bone surface could result expansion bone size , obscure increase non-invasively measured BMD . The current study provide evidence possible TPTD-induced periosteal expansion . From clinical perspective , unclear whether TPTD would preferable osteoporosis medication , zoledronic acid , patient high risk hip fracture . TPTD induce bone formation femur would expect improve bone strength would provide mechanistic basis use TPTD patient high risk hip fracture . The propose project practical ethical way obtain information effect TPTD bone formation proximal femur human . In patient undergoing total hip arthroplasty ( THA ) degenerative joint disease , hip sample greatest interest extract routinely procedure . At time , iliac crest biopsy take minimal added time risk . The protocol follow Specific Aims : In patient undergo elective , noncemented total hip arthroplasty ( THA ) : 1 . To determine early effect 1-34hPTH ( teriparatide ; TPTD 20 mcg ) v placebo , administer subcutaneously daily 6 week , histomorphometric index bone formation cancellous cortical bone proximal femur ( femoral neck intertrochanteric bone ) iliac crest . 2 . To evaluate association change biochemical index bone turnover histomorphometric index bone formation proximal femur ( femoral neck intertrochanteric bone ) iliac crest 6 week treatment TPTD vs. placebo . 3 . To determine circulate osteoblast precursor cell increase 6 week treatment TPTD v Placebo compare change size osteoblast precursor pool change biochemical marker bone formation indices bone formation femur iliac crest .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Age 5090 year old . Male postmenopausal ( woman menses one year ) Degenerative joint disease hip ( osteoarthritis ) require total hip arthroplasty , base radiologic clinical impression . Any contraindication use TPTD . Age young 50 , great 90 year old . Metabolic bone disease osteoporosis . History hyperparathyroidism without surgical correction . Unexplained hypercalcemia . Paget 's disease ( unexplained elevate bone alkaline phosphatase level ) . History metastatic cancer osteosarcoma . Prior radiation treatment . Secondary hyperparathyroidism due vitamin D deficiency renal disease . Active hyperthyroidism excessive thyroid hormone replacement ( TSH normal range ) .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>bone formation rate</keyword>
	<keyword>total hip arthroplasty</keyword>
</DOC>